Afinitor Disperz — CareFirst (Caremark)
Oncocytic/Hürthle cell thyroid carcinoma
Initial criteria
- Progressive and/or symptomatic disease not amenable to radioactive iodine (RAI) therapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months